The present invention relates to optimal compositions useful in treating
HCV infections in humans. These compositions comprise alpha-interferon or
a derivative thereof and an IMPDH inhibitor, wherein the IMPDH inhibitor
is present in an amount such that a ratio of Cavg/Cmin is between 1 to 10,
wherein:
Cavg is average plasma concentration produced by said IMPDH inhibitor in
said human; and
Cmin is estimated trough concentration produced by said IMPDH inhibitor in
said human.
The present invention also relates to methods of producing and using the
optimal compositions to treat HCV infections in humans.
